Adverse drug reaction (ADR) monitoring and pharmacovigilance

Journal of Pharmaceutical Research and Health Care

Volumn 2, Issue 1, 2010, Pages 127-134

  Kavitha, D ^a  

^a ANDHRA UNIVERSITY   (India)

Author keywords

Adverse drug reaction; Pharmacovigilance; Post marketing surveillance

Indexed keywords

DRUG SURVEILLANCE PROGRAM; INDIA; PHARMACIST; PROFESSIONAL PRACTICE; REVIEW;

EID: 77953439550     PISSN: None     EISSN: 09753648     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Brown SD, Landry FJ. Recognizing, reporting, and reducing Adverse Drug Reactions. Southern Medical Journal 2001; 94: 370-372.
2. Murphy BM, Frigo LC. Development, implementation and results of a successful multidisciplinary adverse drug reaction reporting program in a university teaching hospital. Hospital Pharmacy 1993; 28: 1199-1204.
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients - A Meta analysis of prospective studies, Journal of American medical Association 1998; 279(15): 1200-1205.
4. David W Bates, Nathan Spell, David J.Cullen, Elisabeth Burdick, NanLaird, Laura A. Petersen et al. The cost of Adverse drug events in hospitalized patients. Journal of American Medical Association. January.1997; 277(4): 307-311.
5. M.Ramesh, Jayesh Pandit and G.Parthasarathi. Adverse drug reactions in south Indian hospital - their severity and cost involved. Pharmacoepidemiology and drug safety 2003;12(8):687-92.
6. Bordet, S.Gautier, H.Lelouet, B.Dupuis, J. Caron. Analysis of the direct cost of Adverse drug reaction in hospitalised patients. European Journal of Clinical Pharmacology 2001; 56: 935-9
7. Lee A, Beard K 'Adverse Drug Reaction': Pharmacovigilance and The pharmacist, Pharm J.258:592-595,1997.
8. st edition. Orient Longman Private Ltd.2004:86-87.
9. nd international edition. McGraw Hill.2001: 481-495.
10. rd ed. Oxford university press.202: 101-104.
11. Lee B and Turner MW. Food and Drug Administration's adverse drug reaction monitoring program. American journal of hospital pharmacy 1978; 35: 828-832.
12. MC Nell JJ, Gash EA, Mcdonald MM. Post marketing surveillance strengths and limitations.The medical Journal of Australia 1999; 170: 270-273.
13. Brewer T, Colditz GA. Post marketing surveillance and adverse drug reactions: Current Prospective and needs. Journal of American medical association 1999; 281; 824-829.
14. Laurence DR, Bennett PN, Browm MJ. Unwanted effects and adverse drug reactions in: Laurence DR, Bennett PN, Browm MJ. Clinical pharmacology. Eighth ed. Churchill Livingston.1998: 121-137.
15. Edwards IR, Aronson JK. Adverse Drug Reactions: Definition diagnosis and management. Lancet 356: 1255-9
16. Hubes ML, Whittlesea C.M.C., Lusconbe DK. Symptoms or adverse reaction? An investigation into how symptoms are recognized as side effects of medication. Pharmacy journal 2002;269:719-722.
17. Information about Adverse Drug Reaction Advisory Committee(Available from URL:http//www.helth.gov.av/tga/adr/adrfaq.htm)
18. Information about vaccine adverse event reporting system (Available from URL:http//www.vaers.org)
19. Information about national pharmaco vigilance program (Available from URL:http//www)
20. Hurwitz N, Wade O.L. Intensive monitoring of adverse drug reactions to drugs. British Medical Journal 1969;1:531-536.